Use of Daratumumab in Patients With Previously Treated Multiple Myeloma

被引：0
|
作者：
Patel, Ashwin P. [1 ]
机构：
[1] Emory Univ, Sch Med, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 14期
关键词：
D O I：
10.1200/JCO.22.02850
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Daratumumab in multiple myeloma
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Hofmeister, Craig C.
    Joseph, Nisha S.
    Heffner, Thomas L.
    Gupta, Vikas A.
    Sullivan, Harold C.
    Neish, Andrew S.
    Dhodapkar, Madhav, V
    Lonial, Sagar
    CANCER, 2019, 125 (14) : 2364 - 2382
  • [22] Daratumumab in multiple myeloma
    Rajkumar, S. Vincent
    LANCET, 2016, 387 (10027): : 1490 - 1492
  • [23] Daratumumab for multiple myeloma
    Croizier, Carolyne
    Bailly, Sebastien
    BULLETIN DU CANCER, 2018, 105 (11) : 985 - 991
  • [24] Nonmyeloablative allogeneic stem transplantation in patients with previously treated multiple myeloma
    Cudillo, L
    Picardi, A
    Dentamaro, T
    Postorino, M
    Cupelli, L
    Adorno, G
    Caravita, T
    Tamburini, A
    Lasorella, R
    Cox, C
    de Fabritiis, P
    Amadori, S
    BONE MARROW TRANSPLANTATION, 2002, 29 : S158 - S158
  • [25] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [26] Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
    McCudden, Christopher
    Axel, Amy E.
    Slaets, Dominique
    Dejoie, Thomas
    Clemens, Pamela L.
    Frans, Sandy
    Bald, Jaime
    Plesner, Torben
    Jacobs, Joannes F. M.
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Schecter, Jordan M.
    Ahmadi, Tahamtan
    Sasser, A. Kate
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2016, 54 (06) : 1095 - 1104
  • [27] Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens
    De Novellis, Danilo
    Fontana, Raffaele
    Serio, Bianca
    Vaccaro, Emilia
    Guariglia, Roberto
    Morini, Denise
    Rizzo, Michela
    Giudice, Valentina
    Selleri, Carmine
    CANCER MEDICINE, 2024, 13 (14):
  • [28] Outcomes and Management of Red Blood Cell Transfusions in Multiple Myeloma Patients Treated with Daratumumab
    Chari, Ajai
    Satta, Toshihisa
    Tayal, Amit
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Lau, Kenneth
    Morgan, Gillian
    Catamero, Donna
    Escalon, Juliet
    Florendo, Erika
    Verina, Daniel
    Doshi, Parul
    Feng, Huaibao
    Uhlar, Clarissa
    Khan, Imran
    Ahmadi, Tahamtan
    Voorhees, Peter M.
    Mateos, Maria-Victoria
    Arinsburg, Suzanne
    BLOOD, 2015, 126 (23)
  • [29] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
    Mateos, Maria-Victoria
    Sonneveld, Pieter
    Hungria, Vania
    Nooka, Ajay K.
    Estell, Jane A.
    Barreto, Wolney
    Corradini, Paolo
    Min, Chang-Ki
    Medvedova, Eva
    Weisel, Katja
    Chiu, Christopher
    Schecter, Jordan M.
    Amin, Himal
    Qin, Xiang
    Ukropec, Jon
    Kobos, Rachel
    Spencer, Andrew
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (08): : 509 - 518
  • [30] Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma
    Copley, Melissa
    Metheny, Leland
    Klisovic, Rebecca B.
    Malek, Ehsan
    BLOOD, 2022, 140 : 13202 - 13203
12345